Literature DB >> 10190715

In situ detection of mutated hepatitis B virus in microdissected, formalin-fixed liver tissues from patients with chronic hepatitis B.

N Kojima1, N Horiike, K Michitaka, M Onji.   

Abstract

BACKGROUND/AIMS: Hepatitis B virus (HBV) quasispecies have been detected in patients with chronic hepatitis B. In order to elucidate the relationship between HBV mutation and liver cell necrosis in situ, we analyzed sublobule-sized specimens microdissected from formalin-fixed paraffin-embedded liver biopsy tissues taken from patients with chronic hepatitis B.
METHODS: The subjects were 20 patients with chronic hepatitis B. We extracted HBV-DNA from two sublobular regions of HBV-infected liver biopsy tissue, those with the most severe and the mildest hepatitis activity, demonstrated microscopically. The DNA coding sequence of the precore-core region of HBV was determined by amplifying the DNA by the polymerase chain reaction, followed by direct sequencing.
RESULTS: In all seven patients with minimal to mild hepatitis activity, but only 4 of 13 with moderate to severe activity, the amino acid sequence of the precore-core region of HBV obtained from the region with the most severe hepatitis activity showed over 99% homology with the corresponding sequence of HBV obtained from region with the mildest hepatitis activity (p<0.05).
CONCLUSION: The differences between intrahepatic HBVs observed in patients with highly active hepatitis suggest that exacerbation of hepatitis in vivo is related to the appearance of variants in the precore-core region of HBV.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10190715     DOI: 10.1016/s0168-8278(99)80091-9

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  1 in total

1.  Dual gRNAs guided CRISPR/Cas9 system inhibits hepatitis B virus replication.

Authors:  Jie Wang; Zhong-Wei Xu; Shuang Liu; Rui-Yang Zhang; Shan-Long Ding; Xiao-Meng Xie; Lu Long; Xiang-Mei Chen; Hui Zhuang; Feng-Min Lu
Journal:  World J Gastroenterol       Date:  2015-08-28       Impact factor: 5.742

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.